Overview
Status
Active
Registry date
2013-01-10
Share capital
50 000,00 PLN
Registered address
ul. Heroldów 21J/7, 01-991 Warszawa, Poland
Financials
Filing timeliness
No financial statement for 2019 – the filing deadline has passed. 1 of 1 financial statements was filed late (for 2018, 6 days late).
- 2019not filed
- 201821/07/2019
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Authorized Representatives
Roman Pełkowski – President of the Management Board
Manner of representation
The President of the Management Board independently, or two members of the management board jointly, or a member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Marcin Motylage 47 | 100 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
EEC-Travelsp. z o.o. | 54,024.85 USD | 100% | ||
Best Pharma Technologiessp. z o.o. | 13,506.21 USD | 100% |
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 23, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2026-01-09 | Business resumed | |
| 2024-01-08 | Business suspended | |
| 2016-04-27 | Address change (Wybrzeże Kościuszkowskie 31/33, 00-379, Warszawa → Ul. Heroldów 21j/7, 01-991, Warszawa) | |
| 2016-04-27 | PKD change (Removed: 10.8, 18.1, 33.19.Z, 45.11.Z, 46.19.Z, 46.38.Z, 46.45.Z, 46.46.Z, 47.24.Z, 47.25.Z, 47.29.Z, 47.61.Z, 47.62.Z, 47.73.Z, 47.74.Z, 47.75.Z, 49.10.Z, 49.20.Z, 49.32.Z, 49.39.Z, 49.41.Z, 49.42.Z, 52.10.B, 52.23.Z, 53.20.Z, 55, 56, 58.1, 58.2, 59.1, 59.20.Z, 64.20.Z, 64.99.Z, 66.19.Z, 68, 70.22.Z, 72.19.Z, 72.20.Z, 73.1, 73.20.Z, 74.30.Z, 74.90.Z, 77.1, 77.3, 78, 79.9, 82, 85.3, 85.4, 85.5, 85.60.Z, 86.21.Z, 86.22.Z, 86.23.Z, 86.90.E, 91.04.Z, 96.09.Z) | |
| 2013-01-10 | Entered in the register |
FAQ
The main business activity of Pharmanta-Poland focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on January 10, 2013.
The headquarters is located at: ul. Heroldów 21J, 01-991 Warszawa.
The management board consists of: Roman Pełkowski (President of the Management Board).
The share capital of the company is PLN 50,000 (approx. $13,506).
The latest available financial statement covers the period from January 1, 2018 to December 31, 2018.
Last updated: 2026-10-07